Not Medicare Enrolled

Dr. Nasim David Rivera, M.D.

Pediatric Adolescent Medicine · Orlando, FL
1400 N SEMORAN BLVD STE E, Orlando, FL 32807
4078238421
Registered in NPPES since 2006
NPI: 1366401796 verify on NPPES ↗
Moderate
DATA COVERAGE
Data in 2 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. David Rivera from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. David Rivera? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. David Rivera

Dr. Nasim David Rivera is a pediatric adolescent medicine specialist in Orlando, FL, with 20 years of NPI registration.

Between the years covered by Open Payments, Dr. David Rivera received a total of $5,055 from 31 pharmaceutical and/or device companies across 205 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. David Rivera is Moderate — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years of NPI registration $5,055 industry payments

Industry Payment Transparency

Open Payments through 2024 ↗
$5,055
Total received (2018-2024)
Avg $722/year across 7 years
Top 2% in FL for pediatric adolescent medicine
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
31
Companies
205
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →

Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$891
2023
$519
2022
$659
2021
$754
2020
$418
2019
$727
2018
$1,087

Payments by company (2024)

Supernus Pharmaceuticals, Inc.
$282
Tris Pharma Inc
$174
IRONSHORE PHARMACEUTICALS INC.
$132
Vanda Pharmaceuticals Inc.
$64
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)
$56
Lundbeck LLC
$50
Alkermes, Inc.
$29
Otsuka America Pharmaceutical, Inc.
$28
Janssen Pharmaceuticals, Inc
$27
IDORSIA PHARMACEUTICALS US INC
$19
E.R. Squibb & Sons, L.L.C.
$15
Axsome Therapeutics, Inc.
$14
Top 3 companies account for 66.1% of 2024 payments
All-time payments by company (2018-2024) ›
Sunovion Pharmaceuticals Inc.
$989
Tris Pharma Inc
$527
Otsuka America Pharmaceutical, Inc.
$487
Vanda Pharmaceuticals Inc.
$366
Supernus Pharmaceuticals, Inc.
$356
Alkermes, Inc.
$352
Takeda Pharmaceuticals U.S.A., Inc.
$256
Ironshore Pharmaceuticals Inc.
$233
Teva Pharmaceuticals USA, Inc.
$195
ITI, Inc.
$158
Allergan Inc.
$146
IRONSHORE PHARMACEUTICALS INC.
$132
Lundbeck LLC
$131
Avanir Pharmaceuticals, Inc.
$112
AbbVie Inc.
$109
Janssen Pharmaceuticals, Inc
$92
Shire North American Group Inc
$63
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)
$56
IDORSIA PHARMACEUTICALS US INC
$49
Noven Therapeutics, LLC
$38
Almatica Pharma LLC
$32
OWP Pharmaceuticals, Inc.
$28
Neos Therapeutics, LP
$23
Corium, Inc.
$18
Eisai Inc.
$18
Merck Sharp & Dohme LLC
$17
Neurocrine Biosciences, Inc.
$16
E.R. Squibb & Sons, L.L.C.
$15
Indivior Inc.
$14
Axsome Therapeutics, Inc.
$14
PFIZER INC.
$13
Top 3 companies account for 39.6% of all-time payments
Associated products mentioned in payments ›
ABILIFY MAINTENA · ABILIFY MYCITE · ARISTADA · AUSTEDO · Adzenys XR-ODT · Aristada 441 mg · Auvelity · Azstarys · BELSOMRA · BRINTELLIX · CAPLYTA · Dayvigo · Dyanavel XR · Fanapt · GRALISE · HETLIOZ · INGREZZA · INVEGA SUSTENNA · JORNAY PM · Jornay PM 20mg capsules (Bottle of 100) · LATUDA · NUEDEXTA · Onyda XR · PERSERIS · QELBREE · QUILLIVANT XR · QUVIVIQ · Qelbree · REXULTI · SECUADO · Subvenite · TRINTELLIX · Trintellix · UZEDY · VRAYLAR · VYVANSE
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Looking for a pediatric adolescent medicine specialist in Orlando?
Compare pediatric adolescent medicines in the Orlando area by procedure volume, costs, and industry payment transparency.
Browse pediatric adolescent medicines nearby

Geographic Context

Pediatric adolescent medicines in nearby ZIP areas
16
County median income
$77,011
Nearest hospital to ZIP centroid (approximate)
ADVENTHEALTH ORLANDO
2.9 mi

Data Sources

Provider Registry ✓ NPPES NPPES snapshot; verify current record
Medicare Enrollment — Not enrolled N/A
Practice Data — No data N/A
Industry Payments ✓ Open Payments CY 2024
Disciplinary History — Not included N/A

This provider has data in 2 of 4 available federal datasets, with a Data Coverage level of Moderate. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. David Rivera is a pediatric adolescent medicine specialist, with 20 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Does Dr. David Rivera receive payments from pharmaceutical companies?
Yes. Dr. David Rivera received a total of $5,055 from 31 companies across 205 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
What does Data Coverage mean?
Data Coverage (currently Moderate for Dr. David Rivera) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →

Explore related providers

Same specialty & city
Pediatric Adolescent Medicines in Orlando
Browse pediatric adolescent medicines in Orlando ranked by procedure volume and transparency data.
Highest volume
Top Pediatric Adolescent Medicines in FL
Pediatric adolescent medicines ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Pediatric Adolescent Medicines in FL
Which FL pediatric adolescent medicines receive the most from drug and device companies.
By company
Sunovion Pharmaceuticals Inc. Payments to Doctors
See all physicians who received payments from Sunovion Pharmaceuticals Inc.
By company
Tris Pharma Inc Payments to Doctors
See all physicians who received payments from Tris Pharma Inc.
By company
Otsuka America Pharmaceutical, Inc. Payments to Doctors
See all physicians who received payments from Otsuka America Pharmaceutical, Inc.
About this page

This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Industry payment disclosure alone establishes neither wrongdoing nor legality. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →